This is a United States plan; I appreciate the answer is jurisdiction-specific.
The empirical answer seems settled. The explanation does not.
If the honest answer is that nobody knows, I would rather hear that than a plausible story.
Is the standard explanation correct, and if so, what is the evidence for it?
Start with the regulatory basis, because compounding is permitted under specific conditions and those conditions are the whole subject.
A compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.
| Dimension | 503A | 503B outsourcing facility |
|---|---|---|
| Prescription required | Patient-specific | Not required |
| cGMP compliance | Exempt | Required |
| Primary regulator | State board | FDA registration and inspection |
| Release testing | Generally none | Required |
| Operative standard | USP <795> / <797> | cGMP plus USP |
| Practical consequence | Potency varies between sites | Potency is tested before release |
Specifically, beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.
Prohibitions on compounding essential copies of commercially available products are explicit in the relevant regulatory frameworks, with shortage listings as the usual exception.
Facility quality is the dominant variable and cannot be assessed from a website.
Ask which salt form. A different salt is a different active moiety.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswering this needs the jurisdiction, since the framework differs substantially between countries and even between states.
Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.
In practice, facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.
The caveat is that the legal and regulatory position differs by jurisdiction and nothing here is legal advice.
Compounded means unapproved by definition. That is structural, not pejorative.
The relevant distinction is between compounding for an individual patient and compounding at scale, which are regulated differently.
Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.
Specifically, additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.
Beyond-use dating for compounded sterile preparations is governed by published standards keyed to the compounding environment.
Check the beyond-use date and what it was based on.
The honest answer is that a well-run compounding pharmacy is a serious operation and that the variance across facilities is wide.
Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.
Regulatory warnings have specifically addressed salt forms differing from the approved active moiety in this therapeutic area.
The framework is jurisdiction-specific. Check yours rather than a general answer.
edited 11 Dec 2025 by h_pergande — added the placebo-arm figures
In practice, this is an area where the legal position and the quality question are separate and both matter.
Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.
Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.
Ask for the certificate of analysis on the lot. A serious facility has one.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.